Call Our HELPLINE: 1-800-4PD-INFO (473-4636)

Parkinson’s Foundation and Melvin Yahr International Parkinson’s Disease Foundation Announce Merger

Parkinson’s Foundation Establishes ‘Dr. Melvin Yahr Research Award’ to Fund Neurology Fellows, Promote Leadership Diversity in Parkinson’s Research

MIAMI & NEW YORK — The Parkinson’s Foundation today announced its merger with the Melvin Yahr International Parkinson’s Disease Foundation. The foundation, based in New York, is named after Melvin D. Yahr, M.D., a pioneer in Parkinson’s disease (PD) research whose work led to the adoption of levodopa as a revolutionary new Parkinson’s treatment.

“The Parkinson’s Foundation is honored to pay tribute to the many contributions Dr. Melvin Yahr has made to the Parkinson’s community,” said John Kozyak, Esq., chairman of the Parkinson’s Foundation board of directors. “We are proud to continue our long-standing tradition of supporting the next generation of Parkinson’s researchers.”

The Parkinson’s Foundation will honor Dr. Yahr’s legacy by establishing the “Dr. Melvin Yahr Research Award” to promote leadership diversity in Parkinson’s research. The two-year grant will be awarded to one neurology fellow every other year with the intent to fund individuals who have been underrepresented in Parkinson’s research at academic institutions. The foundation also will establish individual “Congress Awards” to help cover travel costs to attend the Congress of the International Association of Parkinsonism and Related Disorders - World Federation of Neurology.

“Dr. Yahr was an expert on Parkinson’s disease whose name is known around the world,” said Lice Ghilardi, M.D., president of the Melvin Yahr International Parkinson’s Disease Foundation. “He has launched many careers in neurology and we are happy to carry on this tradition by funding scholars in his name.”

Dr. Yahr (1917-2004) graduated from New York University and its medical school. He served as Professor of Neurology and Associate Dean of Columbia University’s medical school. With funding from William Black to construct a new research building at Columbia, Dr. Yahr was appointed head of Columbia’s Parkinson’s research team and Scientific Director of the Parkinson’s Disease Foundation, which was founded in 1957 by Mr. Black and has since merged with the National Parkinson Foundation to become the Parkinson’s Foundation.

One of Dr. Yahr’s major career achievements was the development of the Hoehn-Yahr scale in 1967, the first widely used PD rating scale that is still in use today. He published more than 300 scientific papers and helped found the specialty of movement disorders.

The merger is subject to the approval of the Attorney General or the Supreme Court of the State of New York.

About the Parkinson’s Foundation

The Parkinson’s Foundation makes life better for people with Parkinson’s disease by improving care and advancing research toward a cure. In everything we do, we build on the energy, experience, and passion of our global Parkinson’s community. For more information, visit www.parkinson.org, or call 1-800-4PD-INFO (473-4636).

About Parkinson’s Disease

Affecting an estimated one million Americans and 10 million worldwide, Parkinson’s disease is the second-most common neurodegenerative disease after Alzheimer’s and is the 14th-leading cause of death in the United States. It is associated with a progressive loss of motor control (e.g., shaking or tremor at rest and lack of facial expression), as well as non-motor symptoms (e.g., depression and anxiety). There is no cure for Parkinson’s and 60,000 new cases are diagnosed each year in the United States alone.

Thursday, October 26, 2017
The National Parkinson Foundation Awards Four Innovative Research Grants
Wednesday, November 4, 2015

One Million Dollar Investment in Clinical Research in Parkinson’s Disease

MIAMI — The National Parkinson Foundation (NPF) announced today that it has funded four new grants in Parkinson’s disease (PD) research. The four grants target key scientific questions about gender differences in Parkinson’s, cognition and inflammation.

Should Patients and Families Be Considering Tasigna (Nilotinib) Therapy for Parkinson’s Disease? The NPF Recommends Further Study but Not Clinical Use of this Investigational Drug
Wednesday, October 21, 2015

Tasigna (Nilotinib) is a leukemia drug that has recently been tested for safety in a small, phase I clinical trial on about a dozen Parkinson’s disease patients. The study had positive results that certainly warrant the continuation to a phase II trial, however it is too early for patients to seek treatment outside the setting of a clinical trial. The study was very small, and it was not placebo controlled.

NatGeo to Air Live Parkinson's DBS Surgery: What Should You Know?
Tuesday, October 20, 2015

The Parkinson’s Disease Foundation (PDF) has learned that later this week, the National Geographic Channel will air a live television broadcast of deep brain stimulation surgery for Parkinson’s disease (PD).

Parkinson's Disease Foundation and American Parkinson Disease Association Collaborate to Cultivate Future Parkinson's Scientific Leaders
Thursday, October 15, 2015

The Parkinson's Disease Foundation® (PDF®) and the American Parkinson Disease Association (APDA) are pleased to announce their collaboration on Summer Student Fellowships to support research that will help solve, treat and end Parkinson's disease.

PDF Research Advocates Highlight Unmet Needs in Parkinson’s at FDA Meeting
Tuesday, September 29, 2015

The Parkinson’s Disease Foundation (PDF) is pleased to report that five of its Research Advocates represented the community at last week’s Food and Drug Administration’s (FDA) Patient-Focused Drug Development meeting on Parkinson’s Disease in Silver Spring, MD.

National Parkinson Foundation Ohio Chapter Now Serves Entire State
Monday, September 21, 2015

Moving Day® Cleveland, A Walk for Parkinson’s, Slated for June 2016

Columbus — The National Parkinson Foundation (NPF) Central & Southeast Ohio Chapter has officially changed its name to National Parkinson Foundation Ohio. The name change signifies the expansion of service statewide to the approximately 30-50,000 Ohioans with Parkinson’s disease (PD). 

Parkinson's Disease Foundation Mobilizes Community to Address Unmet Needs of Women Living with Parkinson’s
Wednesday, September 16, 2015

The Parkinson's Disease Foundation® (PDF®) is pleased to launch its Women and PD Initiative, the first national coordinated effort dedicated to improving the health and well-being of women living with Parkinson’s disease. The initiative launches this week with a three-day conference in Florham Park, NJ.

Parkinson's Disease Foundation Highlights Under-recognized Aspects of Disease with New Online Educational Series
Tuesday, September 15, 2015

The Parkinson's Disease Foundation® (PDF®) is pleased to announce the launch of its latest series of PD ExpertBriefings — six free online seminars designed to shed light on under-recognized aspects of Parkinson's disease. The series, presented by leaders in Parkinson's research and care, begins today, Tuesday, September 15 at 1:00 PM ET.

PDF-Funded Research Paves the Way to Phase III Drug Trial
Wednesday, September 2, 2015

The Parkinson’s Disease Foundation (PDF) is pleased to announce that research initially launched with PDF funding will be tested in a phase III clinical trial opening in 2016. The study, which two of PDF’s volunteer Research Advocates are helping to oversee, is assessing the potential of the nutritional supplement inosine for the treatment of Parkinson’s disease.

The National Parkinson Foundation’s Medical Director Publishes New Book on Breakthrough Therapies for Parkinson’s Disease
Monday, August 31, 2015

Sequel to 2013 Bestseller, “Parkinson’s Treatment: 10 Secrets to a Happier Life”

Pages

mail icon

Subscribe to get the latest news on treatments, research and other updates.